FOLIC ACID
For many women, an easy way to be sure you're getting enough folic acid is to take a vitamin with folic acid in it. The U.S. Public Health Service recommends that all women who could possibly become pregnant get 400 micrograms (or 0.4 mg) of folic acid every day. This could prevent up to 70% of some types of serious birth defects. But to do this, women need folic acid before they get pregnant. That's why you should always get enough folic acid every day even if you're not thinking about a baby any time soon. Folic acid has been added to some foods, such as enriched breads, pastas, rice, and cereals. A few cereals have 100 percent of the folic acid you need.
No one expects an unplanned pregnancy. But they happen - every day. In fact, about half of all pregnancies are not planned. That's why you should get enough folic acid every day if there's any chance you could get pregnant. Because by the time you know you're pregnant, your baby's brain and spine are already formed.
Folic acid prevents breast cancer
A team of American and Chinese researchers has discovered that folic acid
(folate) is highly effective in preventing breast cancer in both pre- and
postmenopausal women. Their investigation involved 1321 women with breast cancer
and 1382 healthy controls. The women were between the ages of 25 and 64 years
when they enrolled in the Shanghai Breast Cancer Study during 1996-98.
The researchers found a clear correlation between dietary intake of folic acid
and the risk of breast cancer. Women with a daily intake of 345 micrograms or
higher had a 38 per cent lower risk than did women with an intake of less than
195 micrograms – after adjustment for total vegetable, fruit and animal food
intake. The protective effect of folic acid was even more pronounced in women
who also had a high dietary intake of vitamin B6, vitamin B12 and methionine.
Women with a daily intake equal to or higher than 345 micrograms of folic acid,
8.47 micrograms of vitamin B12, 2 mg of vitamin B6, and 1.9 grams of methionine
had a 53 per cent lower risk of breast cancer than did women with daily intakes
at or below 195 micrograms of folic acid, 1.32 micrograms of vitamin B12, 1.35
mg of vitamin B6, and 1.27 grams of methionine.
Researchers believe that folic acid exerts its protective effect by preventing
errors in DNA replication and by helping to regenerate methionine, a vital
component in DNA synthesis. They also point out that both vitamin B12 and
vitamin B6 are vital cofactors required for folic acid to "do its job". NOTE:
Most multivitamins have levels of folic acid, vitamin B6 and vitamin B12 well
above the levels found to be beneficial in the Shanghai study.
Although pancreatic cancer accounts for only 2 per cent of all cancers worldwide
it is the fifth leading cause of cancer deaths in the US. The five-year survival
rate is less than 5 per cent. Researchers at the National Cancer Institute and
the Finnish National Public Health Institute now report that an adequate folic
acid intake can materially reduce the risk of developing the cancer. Their study
included over 27,000 healthy male smokers aged 50 to 69 years when enrolled in
1985. Thirteen years later 157 of the men had developed cancer of the pancreas.
A review of dietary records revealed that the men with a daily dietary folate
intake of more than 373 micrograms/day had half the risk of pancreatic cancer
than did the men with an intake of less than 280 micrograms/day. This
significant risk reduction held true even after adjusting for other potential
risk factors. As expected, the most serious risk factor was smoking. Men who
smoked more than 25 cigarettes a day had an 82 per cent higher risk than men who
smoked less than 14 a day. The researchers found no correlation between the risk
of pancreatic cancer and alcohol consumption or dietary intake of methionine,
vitamin B6 or vitamin B12.
Supplementing with folic acid seemed to have a slightly negative effect. The
researchers point out that the supplement takers had significantly more health
and alcohol-related problems than did the non-takers and that the number of
supplement takers was too small to draw statistically significant conclusions.
They caution that the issue could be clouded by earlier findings from animal
experiments that, while folic acid supplementation may be effective in
preventing cancer from starting, it may actually enhance tumor development at a
later stage.
The U.S. government has mandated the fortification of all cereal grains
with 0.14 mg (140 micrograms) of folic acid per 100 grams of grain. The aim of
this measure is to reduce the risk of women giving birth to babies with neural
tube defects (spina bifida). The fortification would theoretically supplement a
person's diet with about 0.1 mg (100 micrograms) of folic acid per day.
Folic acid supplementation has also been found useful in lowering homocysteine
levels and thereby reducing the incidence and mortality from ischemic heart
disease (angina and heart attack). A dosage of 1 mg (1000 micrograms) per day
has been found to result in about a 25 per cent decrease in homocysteine
concentration; this is estimated to correspond to a 15 per cent reduction in
mortality from ischemic heart disease. Higher dosages (up to 5 mg/day) have not
been found to have any greater effect than the 1 mg/day dose. British
researchers have now addressed the question of how much folic acid (in
supplement form) is needed to achieve the maximum homocysteine reduction. Their
clinical trial involved 151 patients with ischemic heart disease who were
randomized to receive 0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1 mg or a placebo daily
for a three-month period. The participants' blood levels of folate and
homocysteine were measured before the start of supplementation, at the end of
the supplementation period, and three months later. The maximum median reduction
in homocysteine levels (23 per cent) was observed at a supplementation level of
0.8 mg/day. The currently recommended daily intake of 200-400 micrograms/day
achieved only a 10 per cent reduction in homocysteine levels. Homocysteine
levels returned to their pre-trial levels after three months without
supplementation indicating that folic acid supplementation must be continuous
and indefinite if homocysteine levels are to be kept in check. The researchers
conclude "It would be reasonable for clinicians to consider advising patients
with ischemic heart disease to take 0.8 mg (800 micrograms) of folic acid each
day."
People with inflammatory bowel disease (Crohn's disease and ulcerative
colitis) tend to be at greater risk for thromboembolic events (blood clots) such
as stroke and peripheral venous thrombosis. Researchers at the Chaim Sheba
Medical Center believe they may have found the reason for this. They studied 105
men and women with active Crohn's disease and compared their blood levels of
homocysteine (a known risk factor for blood clots), folic acid and vitamin B12
to the levels found in 105 healthy controls. They found that homocysteine levels
were significantly higher in patients with mild to moderately active Crohn's
disease and that folic acid and vitamin B12 levels were significantly lower. The
average level of folic acid was 5.9 pg/mL (normal range is 5 to 17 pg/mL). The
researchers point out that it is well established that increased folate levels
correspond to lower homocysteine levels. They conclude that patients with
Crohn's disease may benefit from supplementing with folic acid.
Several studies have concluded that high homocysteine levels are associated with
coronary artery disease (CAD). It is believed that homocysteine promotes
atherosclerosis through increased oxidative stress and by "encouraging"
dysfunction of the lining of the arteries (endothelial dysfunction). It is
generally accepted that folic acid supplementation will lower homocysteine
levels, but whether folic acid supplementation will also reduce the endothelial
dysfunction responsible for the initiation and progression of atherosclerosis is
less certain.
Medical researchers at the Queen Elizabeth II Health Sciences Centre now report
that supplementation with 5 mg/day of folic acid significantly decreases
endothelial dysfunction. The extent of endothelial dysfunction is determined by
measuring the blood flow through the brachial artery in the arm (flow-mediated
dilation or FMD). The clinical trial included 75 patients with CAD. The patients
were randomized into three groups. One group took 5 mg of folic acid daily for
four months; the second group took 5 mg of folic acid plus 2000 mg of vitamin C
plus 800 IU of vitamin E per day; the third group was given a placebo. At the
end of the trial patients in the folic acid group had increased their blood
plasma level of folate by 475 per cent (from 14 nmol/L to 80 nmol/L) and
decreased their homocysteine level by about 11 per cent. FMD improved
significantly as well (from 3.2 to 5.2 per cent). Patients in the folic acid
plus antioxidant group increased their folate level by 438 per cent, reduced
homocysteine by 9 per cent, and improved FMD from 2.6 to 4.0 per cent. The
researchers point out that the FMD improvement seen in the folic acid
supplemented groups is similar to that seen with statin drugs and ACE
inhibitors. They conclude that four months of folic acid supplementation is safe
and significantly reduces endothelial dysfunction in patients with established
coronary atherosclerosis.
High homocysteine levels are associated with an increased risk of heart disease.
High homocysteine levels have also been linked to a relative folic acid
deficiency. Researchers at the Centers for Disease Control and Prevention now
report that low blood levels of folic acid are associated with a substantially
increased risk of dying from cardiovascular disease. Their study involved 689
adults aged between 30 and 75 years who were free of heart disease at the start
of the study in 1976-1980. After 12 to 16 years of follow-up 122 of the
participants without diabetes had died - 49 of them from heart disease. Among
the participants with diabetes, 52 in all, 25 died - 12 of them from heart
disease.
In the non-diabetic group there was a clear association between blood levels of
folate and death from heart disease. The participants with folate levels below
10 nmol/L had a 2.64 times higher age and sex adjusted risk of dying from
cardiovascular disease than did the participants with levels above 16.8 nmol/L.
Even when adjusting for other risk factors (education level, race, cigarette
smoking, alcohol consumption, cholesterol levels, blood pressure, and body mass
index) the death rate among the participants with low folate status was still
2.28 times higher than among the people with higher levels. The observations
made in the non-diabetic group tended to parallel those in the diabetes group,
but because of the small sample size in the diabetes group the observed trends
were not statistically significant.
The researchers conclude that at least a third of the participants had folate
levels at baseline (1976-1980) so low that they would be in the high-risk
category for dying from cardiovascular disease. They urge further work to
determine if recent efforts to fortify the US food supply with folic acid are
sufficient to decrease the proportion of the population at risk for heart
disease because of insufficient folate levels.
Dr. Melvyn Werbach, MD of the UCLA School of Medicine has just published a
thorough review of nutritional deficiencies involved in chronic fatigue syndrome
(CFS). These include deficiencies in vitamin C, coenzyme Q10, magnesium, zinc,
sodium, l-tryptophan, l- carnitine, essential fatty acids, and various B
vitamins. He points out that there is some evidence that the deficiencies are
caused by the disease itself rather than by an inadequate diet. He suggests that
the deficiencies not only contribute to the symptoms of CFS but also impair the
healing process. Although the results of supplementation trials involving CFS
patients have been inconclusive so far Dr. Werbach nevertheless recommends that
CFS patients be given large doses of certain supplements for at least a trial
period to see if their symptoms improve. His recommendations are:
The supplements should be administered with medical supervision and
accompanied by a high- potency vitamin/mineral supplement for the duration of
the trial. [95 references]
Studies have shown that low concentrations of folic acid (folates) in the
blood are associated with an increased risk of dementia and Alzheimer's disease
(AD). Researchers at the University of Kentucky now report that low folate
levels are directly associated with a high degree of atrophy of the cerebral
cortex. Their study involved 30 nuns who had blood samples drawn and analyzed
prior to their death between the ages of 78 and 101 years. Autopsies of the
brains showed a clear negative association between folate levels and atrophy of
the neocortex and this association was especially strong among the nuns who had
been diagnosed with Alzheimer's disease. The average folate level in the nuns
with significant AD was 45 nmol/L as compared to 61 nmol/L in the nuns without
significant AD. It is interesting that the average blood levels of folate was
104 nmol/L in the nuns taking multivitamin pills as compared to only 36 nmol/L
in those not taking supplements.
The researchers also found that the nuns with moderate to severe
atherosclerosis in the arteries supplying the brain had an average blood folate
level of only 34 nmol/L while those with minimal atherosclerosis had a level of
75 nmol/L. They conclude that a folate deficiency is associated with increased
atrophy of the neocortex, particularly in patients with Alzheimer's disease.
A high blood level of homocysteine (a sulfur-containing amino acid derived from
methionine) has been associated with the development of atherosclerosis. High
homocysteine levels can be reduced by supplementation with folic acid; however,
it is still uncertain whether this reduction actually lowers the risk of
atherosclerosis. Now researchers at the University Hospital Vrije Universiteit
report evidence that supplementation with folic acid and vitamin B6 is
associated with a decreased occurrence of abnormal exercise electrocardiographs
- important markers for atherosclerosis. The study involved 158 siblings of 167
patients with premature atherothrombotic disease. The study participants
(siblings) had no signs of arterial disease when entering the study, but were
obviously at greater risk of developing atherosclerosis than normal. The
participants underwent a methionine-loading test at the start of the study and
were subsequently divided into two groups. One group of 104 had high
homocysteine levels after the methionine-loading test while the second group of
54 siblings had normal levels. Each group was subsequently randomized to receive
either 5 mg folic acid plus 250 mg vitamin B6 daily for a two-year period while
the other group received a placebo. At the end of two years all participants had
an electrocardiogram, an ultrasound measurement of the carotid and femoral
arteries, and a determination of their ankle-brachial pressure index at rest and
after exercise. As expected, the vitamin treatment was associated with a
significant drop in both fasting homocysteine concentration and postmethionine
homocysteine concentration. Blood plasma content of folic acid increased 13-fold
and that of vitamin B6 9-fold in the supplement group. There was no apparent
effect of vitamin treatment on ankle-brachial pressure indices or ultrasound
measurements; however, the incidence of new abnormal exercise electrocardiograms
was much lower in the vitamin group (6 versus 14 in the placebo group). The
researchers conclude that vitamin therapy lowers the risk of an abnormal
exercise electrocardiogram by 60 per cent independent of other risk factors such
as age, sex, baseline level of postmethionine homocysteine, cholesterol levels,
smoking habits, and the presence of hypertension or diabetes. Although the trial
involved participants at high risk for atherosclerosis the researchers see no
reason why the results should not be applicable to healthy individuals.
Niacin (vitamin B3) has been used effectively to reduce elevated
cholesterol levels. Niacin therapy is particularly desirable because it reduces
the level of low- density lipoproteins (LDL - the "bad" cholesterol) and
increases the level of high-density lipoproteins (HDL - the "good" cholesterol).
A recent trial which evaluated the effect of treating high cholesterol levels
with both niacin and the cholesterol-lowering drug colestipol found that the
treated patients increased their blood plasma levels of homocysteine. High
homocysteine levels have been associated not only with an increased risk for
heart disease, but also with an increased risk for stroke, intermittent
claudication, and hypothyroidism.
Researchers at the Eli Lilly Research Laboratories and the Oregon Health
Sciences University have now completed a study designed to determine whether it
was the colestipol or the niacin which caused the increase in homocysteine
levels. The trial involved 52 patients with peripheral vascular (arterial)
disease who were randomized to receive a placebo or up to 3000 mg/day of
crystalline niacin for 48 weeks. At 18 weeks after the start of the study the
average blood level of homocysteine had increased by 55 per cent (from 13.1
micromol/L to 21.1 micromol/L) in the niacin group. This increase is highly
significant and according to other research corresponds to an increase in the
risk of coronary artery disease of about 80 per cent. Of course, this increase
in risk would be at least partially offset by the reduction in risk caused by
the cholesterol reduction due to niacin therapy. The researchers point out that
homocysteine levels can be effectively lowered by supplementation with folic
acid and vitamins B6 and B12. They urge further studies to determine whether
supplementation with these vitamins would be beneficial to patients undergoing
long-term niacin therapy.
High blood levels of the amino acid homocysteine have been associated with
an increased risk of atherosclerosis. Homocysteine is formed in the body from
methionine (an amino acid found in proteins) in a process that can be blocked by
folic acid and vitamins B6 and B12. High homocysteine levels can induce
endothelial dysfunction (a narrowing of the arteries) which in turn is believed
to be a precursor of atherosclerosis. Researchers at the National Taiwan
University Hospital now report that homocysteine-induced endothelial dysfunction
can be avoided or very significantly ameliorated by supplementing with folic
acid and vitamins B6 and B12.
The study involved two men and fourteen women between the ages of 41 and
55 years. At the start of the study all participants had their blood levels of
homocysteine and their blood flow through the brachial artery measured after a
10-14 hour overnight fast. They were then given an oral methionine loading test
to simulate the intake of a high protein meal. Four hours later their average
homocysteine level had increased from 7 micromol/L to 22.7 micromol/L and the
blood flow (flow-mediated vasodilation) had decreased by 40 per cent. The
experiment was repeated, but this time 5 mg of folic acid was given together
with the methionine; the results were similar to those obtained in the first
experiment indicating that folic acid does not act immediately as an "antidote"
to a high intake of methionine. The participants were then given 5 mg of folic
acid, 100 mg of vitamin B6, and 0.5 mg of vitamin B12 daily for five weeks. At
the end of the five weeks their average homocysteine level had decreased to 5.2
micromol/L. The methionine loading test was repeated. Four hours later the
average homocysteine level among the participants had increased to 17
micromol/L, but there was no statistically significant difference in blood flow
before and after the methionine loading test. The researchers conclude that
short-term (five weeks) administration of folic acid and vitamins B6 and B12
will reduce post-methionine load homocysteine levels and eliminate or ameliorate
endothelial dysfunction (an early manifestation of atherosclerosis).
A study of the vitamin C status of 677 noninstitutionalized elderly people (age
60 to 98 years) was carried out in the Greater Boston area between August 1981
and December 1983. The study was based on detailed blood analyses and three-day
food intake and nutrient supplement records. The study involved 235 males (82 of
whom used vitamin C supplements) and 442 females (195 of whom used supplements).
The average daily vitamin C intake from diet alone was 142 and 136 mg/day for
males and females respectively. The mean daily supplement dose was 300 mg. The
study found no significant correlation between plasma ascorbic acid (AA) level
and age; however, there was a clear correlation between vitamin C intake and
plasma AA level. None of the subjects taking supplements were found to be
deficient in plasma AA levels; however, 6% of male non-users and 3% of female
non-users were found to be marginally deficient. There was no significant
correlation between vitamin B-6 status and plasma AA level nor was vitamin B-12
status affected. The study supports the hypothesis that vitamin C spares vitamin
E in elderly people. Neither copper nor iron absorption seemed to be affected by
plasma AA levels. However, the folate status was substantially better (by 25%)
in supplement users as compared to non-users.
The Public Health Service in the U.S.A. recently issued a statement urging
women of child-bearing age to ensure that they consume 400 micrograms of folic
acid a day. Folic acid is present in leafy dark vegetables and citrus fruits,
but even a well balanced diet may not provide 400 micrograms per day; thus the
need for supplementation. Recent studies in England and Hungary have shown that
folic acid is important in preventing neural tube defects. Dr. Godfrey Oakley of
the Centers for Disease Control estimates that 2,500 children are born with
neural tube defects in the United States each year. He predicts that one half to
three quarters of these cases can be prevented if women of child-bearing age
ensure an adequate intake of folic acid at all times. NOTE: Neural tube defects
usually occur before a woman realizes that she is pregnant.
It is becoming increasingly clear that fruits, vegetables, fiber, and
antioxidant vitamins are potent protectors against many forms of cancer. Now
folic acid has been added to the list. A recent study shows that increased
dietary intake of folic acid significantly reduces the risk of developing
adenomas (tumors) of the colon and rectum. Dr. Gladys Block of the University of
California points out that only 9% of all Americans consume the recommended five
or more servings a day of fruits and vegetables. She recommends that serious
consideration be given to fortifying food and/or urging people to use
antioxidant supplements so as to reduce the incidence of cancer.
Evidence is mounting that a high intake of fruits and vegetables is protective
against most cancers. It is not entirely clear which components of the fruits
and vegetables provide the protection but vitamin C and beta carotene have long
been top contenders. Now researchers at the Harvard Medical School report that
folic acid may provide significant protection against colon cancer. The
scientists found that men and women with a high intake of folic acid (including
supplements) had a 35 per cent less risk of developing adenomatous colon polyps
(the precursors to colon cancer) than did people with a low intake. A high fiber
intake was also found to lower the colon adenoma risk. Thus people who consumed
about 30 grams/day of fiber had a 50 per cent lower risk than did people who
consumed about 12 grams/day. The researchers also report on the latest findings
in the Nurses' Health Study concerning breast cancer. Between 1980 and 1988
about 1500 cases of breast cancer occurred in the study group. The scientists
found no correlation between the risk of breast cancer and the intake of fat or
the intake of vitamins C and E. However, a high intake of vitamin A was found to
correspond to a 20 to 30 per cent reduction in breast cancer risk. The
researchers believe that both beta carotene and preformed vitamin A from animal
sources (including supplements) have a protective effect. They point out that
women who already have a high dietary intake of vitamin A may benefit little
from further supplementation; however, among women whose dietary intake was low,
the scientists found a 50 per cent reduction in breast cancer risk associated
with the use of vitamin A supplements.
Dr. Abram Hoffer, a world-renowned psychiatrist in Victoria, reports on the
successful treatment of six patients with atrial fibrillation. One 76 year old
physician who suffered from atrial fibrillation was completely cured after
starting a vitamin supplementation program which included megadoses of niacin
and folic acid. Other patients report complete disappearance of their irregular
heart beat symptoms after supplementing with high doses of niacin, folic acid,
and vitamin B-12. Dr. Hoffer believes that one of the main causes of atrial
fibrillation is excessive stress. High levels of stress release large amounts of
adrenalin which in turn is oxidized to adrenochrome. Adrenochrome is known to
cause fibrillation and other cardiac dysfunctions. Adrenochrome is a natural
free radical and is primarily produced in the heart tissue, but circulates in
the blood throughout the body. It can cross the blood-brain barrier and
excessive amounts of it are believed to be a main cause of schizophrenia.
Antioxidants protect against the formation of excessive amounts of adrenochrome
and schizophrenics have been successfully treated with large amounts of niacin
and ascorbic acid. Penicillamine has also been successfully used in the
treatment of schizophrenia. Dr. Hoffer points out that adrenochrome is not all
bad. He believes that the leucocytes use adrenochrome to destroy abnormal cells
like cancer cells and that we therefore need a certain amount of adrenochrome in
order to control cancer. The fact that schizophrenics rarely develop cancer
supports this hypothesis. Dr. Hoffer concludes that we need a certain amount of
stress in order to produce enough adrenochrome to enable our leucocytes to kill
bacteria and tumor cells. However, we also need an adequate supply of natural
antioxidants such as vitamins C and E and beta-carotene in order to neutralize
an excess of adrenochrome after its work is done.
Several recent studies on the causes of coronary disease have concluded
that a high blood level of homocysteine is an important risk factor. A recently
completed study, the Physicians' Health Study, showed that men with a high
homocysteine level had a three times higher risk of suffering a myocardial
infarction (heart attack) than did men with lower levels. Elevations of
homocysteine levels can be due to relatively rare genetic defects but are most
likely caused by a lack of folate (folic acid) in the diet. Studies have shown
that the level of homocysteine in the blood is inversely proportional with the
level and dietary intake of folate. A minimum daily intake of 400 micrograms per
day of folate is required to maintain a stable low level of homocysteine. A
folate intake of 1 to 2 mg per day, which is generally safe, is usually
sufficient to reduce high homocysteine levels even if they are not due to
inadequate folate consumption. It is estimated that 40 per cent of Americans get
too little folate and that over 20 per cent have homocysteine levels high enough
to result in vascular disease.
Researchers at the Harvard Medical School report that heavy drinking (more
than two drinks a day) combined with a low intake of folate and methionine
triples the risk of developing colon cancer. Their study involved almost 48,000
male health professionals in the United States and covered the period 1986 to
1992. During this period 205 new cases of colon cancer were diagnosed in the
study group. The researchers also discovered that men who drank more than two
drinks per day, but had a high folate or methionine intake, had no greater risk
of developing colon cancer than did non-drinkers. The greatest protective effect
was found with a methionine intake in excess of 2.44 grams/day and a folate
intake of 646 micrograms/day or greater. A high methionine and folate intake did
not significantly lower the risk of getting colon cancer among light drinkers
and non-drinkers. The risk of getting colon cancer was somewhat higher among
wine drinkers than among beer and liquor drinkers. The researchers recommend
that alcohol drinkers increase their intake of methionine-rich foods (poultry,
fish, and low-fat dairy products); they do not recommend supplementation with
methionine as an excess can increase blood homocysteine levels. A high
homocysteine level is now believed to be a risk factor for coronary heart
disease. A high intake of folate-rich foods (fresh fruit, vegetables, and
whole-grain foods) is also recommended including the use of multivitamin
supplements if necessary. The researchers believe that the combination of large
amounts of alcohol and insufficient amounts of methionine and folate in the diet
leads to abnormalities in the methylation of DNA. This may contribute to the
development of cancer by activating tumor development genes and deactivating
tumor suppressor genes. (88 references)
Researchers at the California Birth Defects Monitoring Program and the Oakland
Children's Hospital report that mothers can decrease their risk of giving birth
to a child with orofacial clefts (cleft lip or palate) by increasing their
intake of folic acid prior to and immediately following conception. The
investigation involved 731 mothers who had given birth to a child with an
orofacial cleft and 734 mothers with a non-malformed child. The researchers
found that mothers who had taken multivitamins containing folic acid (0.4-0.8
mg) during the period from one month before through two months after conception
had a 25 to 50 per cent reduction in the risk of giving birth to a child with
orofacial clefts. Earlier research has shown that a mother who has already given
birth to one child with orofacial clefts can reduce her risk of having another
child with orofacial clefts by a factor of six if she takes multivitamin pills
and 10 mg/day of folic acid.
Folic acid
helps prevent coronary heart disease
A high level of homocysteine in the blood has been clearly implicated in
heart disease, stroke and peripheral vascular disease. Homocysteine is an amino
acid which is not found in protein as such, but is involved in the metabolism of
other amino acids (methionine and cysteine). The average blood level of total
homocysteine in male adults is about 10 micromol/L. Now researchers at the
University of Washington confirm that people with a higher than normal level of
homocysteine have a greater risk of developing vascular disease. The researchers
evaluated 17 studies dealing with the link between homocysteine levels and the
risk of coronary artery disease (CAD). They found that men with a level of 15
micromol/L had a 60 per cent greater risk of developing CAD while the increased
risk for women was 80 per cent. The risk for cerebrovascular disease (stroke)
was found to be almost twice as high in men and women with elevated (15
micromol/L) homocysteine levels. The risk of developing peripheral vascular
disease (eg. intermittent claudication) was found to be almost seven times
higher among people with elevated homocysteine levels. The researchers conclude
that a high homocysteine level is an independent risk factor for vascular
disease and that a 5 micromol/L elevation results in the same increase in CAD
risk as a cholesterol increase of 0.5 mmol/L (20 mg/dL).
The researchers also evaluated 12 studies concerning the connection
between dietary intake of folic acid and homocysteine level. They found that
folic acid is very effective in lowering homocysteine levels. An intake of 400
micrograms per day (the level found in most supplements) lowers the homocysteine
level by about 6 micromol/L. The researchers conclude that over 44,000 lives
could be saved every year if just half the population of the United States were
to supplement with 400 micrograms per day of folic acid. Unfortunately, recent
surveys have shown that 88 per cent of American adults have a daily intake of
folic acid below 400 micrograms. The researchers warn that an increased intake
of folic acid may mask a vitamin B-12 deficiency and recommend that 1 mg of
vitamin B-12 be added to all supplements containing 400 micrograms of folic
acid. They also recommend that consideration be given to fortifying grain
products with 350 micrograms of folic acid per 100 grams of grains. This
strategy would have the added advantage of making it easier to prevent neural
tube defects in new born babies.
It is generally accepted that a high blood level of homocysteine is a
significant risk factor for cardiovascular disease. Several studies have found
that patients with coronary heart disease have homocysteine levels which are 20
to 30 per cent (2 to 3 micromol/liter) higher than those of healthy control
subjects. A recent study found that a 5 micromol/l increase in homocysteine
level is associated with a 60 to 80 per cent increase in the risk of coronary
artery disease and a 50 per cent increase in the risk of cerebrovascular disease
(stroke). Researchers from the University of Bergen now report that homocysteine
levels are closely linked with other known risk factors for cardiovascular
disease. Their study involved a total of 7,591 men and 8,585 women between the
ages of 40 and 67 years. None of the participants had a previous history of
diabetes, hypertension, coronary heart disease or cerebrovascular disease. The
researchers found that men tend to have higher homocysteine levels than women
and that these levels increase significantly with age. Cigarette smoking is
closely connected with homocysteine levels and women smokers tend to have higher
levels than male smokers. When age, sex, and cigarette smoking is combined the
effect becomes vastly magnified. A 65-67 year old man who is a heavy smoker has
a homocysteine level 4.8 micromol/l higher than a never-smoking woman aged 40-42
years; this would correspond to a 60 to 80 per cent higher risk for coronary
heart disease.
Exercise has a beneficial effect on homocysteine levels with vigorous
exercise in the 40-42 year age group having homocysteine levels 0.8-0.9
micromol/l lower than sedentary people. A low diastolic blood pressure and heart
rate were both associated with benefically lower homocysteine levels. Serum
cholesterol levels were also found to be related to homocysteine levels with
lower cholesterol levels corresponding to lower homocysteine levels. People who
took vitamin supplements, which usually contain folic acid, were found to have
an average 1.35 micromol/l lower homocysteine level than people who did not
supplement. A diet rich in fresh fruit and vegetables was also found to be
beneficial with people eating fruit and vegetables at least six times a week
having a 0.79 micromol/l lower homocysteine level than people eating fruit and
vegetables once a week or less. The researchers conclude their report by raising
the crucial question "Is a high homocysteine level the cause of cardiovascular
disease or merely a marker of susceptibility to cardiovascular disease?" The
Norwegian team believe that high homocysteine levels actually may cause vascular
disease and raise the intriguing possibility that people who are at an elevated
risk for cardiovascular disease (smokers, sedentary people, people with high
blood pressure and cholesterol levels, and older people) may actually lower
their risk by increasing their intake of vitamins or more specifically, folic
acid.
Evidence is rapidly accumulating to the effect that a high homocysteine
level in the blood is a potent risk factor for cardiovascular disease.
Homocysteine is an amino acid formed in the metabolism of methionine. A high
level of homocysteine can be inherited, but far more often is due to a
deficiency of the vitamins required to metabolize it (folic acid, vitamin B- 6,
and vitamin B-12). A team of British and Norwegian medical researchers now
report that men with a high homocysteine level have a vastly increased risk of
suffering a stroke (ischemic). Their study involved 5,661 middle-aged men whose
blood was sampled in the period 1978 to 1980. By 1991 141 of the men had
suffered a stroke. The researchers compared the homocysteine level in the blood
from the stroke victims with the level in blood from matched controls who had
not had a stroke or heart attack during the follow-up period. They found that
men with a total homocysteine level of more than 15.4 micromol/liter had an
almost five times greater risk of having a stroke than did men with a more
normal level of less than 10.3 micromol/liter. The increased stroke risk held
true even after adjusting for obesity, hypertension, diabetes, cigarette
smoking, alcohol consumption, social class, lung capacity, and level of HDL
cholesterol. Elevated homocysteine levels can be normalized by ensuring an
adequate intake of folic acid and other B vitamins.
A team of researchers from the University of Ulster and Trinity College in
Dublin report that eating folate-rich foods such as broccoli and spinach does
not result in improved folate status. An adequate folate status is especially
important in women of child-bearing age as low folate levels in the blood can
lead to the birth of babies with neural tube defects. Recent research has also
shown that an adequate folate status is crucial in the prevention of heart
disease. The study involved 41 women aged 17 to 40 years. The women were
randomly assigned to one of five groups. Group I was given 400 micrograms/day of
a folic acid supplement, Group II received 400 micrograms/day of folate by
eating folic-acid-fortified foods, Group III received 400 micrograms/day of
folate through the consumption of folate-rich food, Group IV received dietary
advice on how to increase their intake of folate from food, and Group V served
as a control group. At the end of the three-month experiment only the women in
Groups I and II showed a significant increase in the folate content of their red
blood cells. The researchers conclude that it is misleading to advise women to
rely on the consumption of folate- rich foods as a means of maintaining an
adequate folate status. The only way an adequate status can be ensured is by
taking supplements or by consuming foods fortified with folic acid.
Researchers at
Health Canada report that a lack of folate (folic acid) increases the risk of
death from coronary heart disease (CHD) significantly. Their study began in 1970
and involved 5056 men and women aged 35 to 79 years. During the 15-year
follow-up period there were 165 deaths from CHD. The researchers conclude that
people with low folate levels (<6.8 nmol/L [3 ng/mL]) have a 69 per cent greater
risk of dying from CHD than do people with high levels (>13.6 nmol/L [6 ng/mL]).
They also confirm that smoking, hypertension, diabetes, and high cholesterol
levels are potent risk factors for cardiac death with relative risk rates of
1.72, 2.37, 2.26, and 2.91 respectively. Low folate levels have also been linked
to an increased risk of carotid artery stenosis, neural tube defects, cervical
dysplasia, and rectal cancer. It is believed that an adequate level of folate is
required in order to avoid high blood levels of homocysteine, a known risk
factor for both CHD and cerabrovascular disease. The researchers point out that
an estimated 88 per cent of American adults consume less folate than required to
produce low, stable homocysteine levels. They also point out that the
bioavailability (absorption) of folate from food is significantly less than that
from folic acid supplements.
Researchers at the
Harvard Medical School confirm that a high blood level of homocysteine is a
potent risk factor for a first heart attack (myocardial infarction).
Homocysteine is an amino acid formed during the metabolism of methionine (an
amino acid found in proteins). The researchers measured the blood plasma levels
of homocysteine, vitamin B-6, vitamin B-12, and folate (folic acid) in 130
Boston area residents who had suffered a first heart attack. The results were
compared to levels found in 118 matched controls. The homocysteine levels were
an average 11 per cent higher in the heart attack victims than in the controls.
A high homocysteine level (>11.2 micromol/L) corresponded to a five-fold
increase in heart attack risk over the incidence rate at a low level (<7.2
micromol/L). The increase in risk was linear with a 3 micromol/L increase in
homocysteine level corresponding to a 35 per cent increase in heart attack risk.
The researchers also found that high blood levels of vitamin B-6 and folic acid
provide significant protection against heart attacks. No clear assocation was
found between vitamin B-12 levels and heart attack risk. There was a strong
inverse relationship between homocysteine levels and folate levels indicating
that an adequate folate intake is essential to normalizing homocysteine levels.
The researchers found that homocysteine levels were lowest at a folate intake of
350-400 micrograms/day and recommend a daily folate intake of 400 micrograms/day
(the current RDA is 200 micrograms/day).
Systemic lupus erythematosus (SLE) patients have an increased risk of
suffering strokes, heart attacks, and other arterial thrombotic events such as
gangrene of the fingers. It is believed that this higher risk is at least
partially related to a greater propensity among SLE patients to develop
premature atherosclerosis. High concentrations of homocysteine (a
sulphur-containing amino acid) have previously been linked to an increased risk
of stroke and coronary artery disease. Now researchers at the Johns Hopkins
Medical Institutions report that many SLE patients have high homocysteine levels
and that these higher levels correspond to a significantly increased risk for
stroke and other thrombotic events. The study involved 337 SLE patients who were
followed for an average of 4.8 years. The average age of the patients was 35
years and 93 per cent of them were women. The researchers found that 15 per cent
of the patients had raised homocysteine levels (greater than 14.1
micromol/liter). They also noted a strong inverse correlation between
homocysteine levels and the levels of folic acid and vitamin B- 6 in the blood.
After adjusting for other relevant risk factors the researchers conclude that
SLE patients with elevated homocysteine levels have a 2.4 times higher risk of
having a stroke and a 3.5 times higher risk of having an arterial thrombotic
event. The researchers suggest that supplementation with folic acid and vitamin
B-6 may help prevent thrombotic events in SLE patients. Other studies have found
a clear inverse correlation between homocysteine levels and vitamin B-12 levels.
This correlation was not observed in the present study - most likely because the
patients were relatively young and therefore less likely to be deficient in
vitamin B-12.
Colorectal adenomas are benign tumors (polyps) in the large intestine that are
believed to be precursors of colon cancer. Researchers at the University of
North Carolina now report that women with a high intake of folate (folic acid)
and men with a high intake of vitamin E have a much reduced risk of developing
colorectal adenomas. Their study involved 645 patients who underwent colonoscopy
in the period between July 1988 and March 1991. Of these patients, 236 were
found to have adenomas or cancer while 409 had no polyps and were used as a
control group. After adjusting for other variables the researchers conclude that
women with an average (mean) daily intake of 398 micrograms or more of folate
have a 60 per cent reduced risk of developing colorectal adenomas as compared to
women with a mean daily intake of 130 micrograms or less. The RDA of folate is
only 180 micrograms. High intakes of iron (25 mg/day or more) and vitamin C (278
mg/day or more) were also found to have a protective effect among women. Among
men the most protective micronutrient was vitamin E. Men whose daily vitamin E
intake averaged 34 IU or higher were found to have a 65 per cent reduction in
their risk of developing colorectal adenomas as compared to men with a mean
daily intake of 5 IU or less. The RDA of vitamin E for men is only 10 IU. A high
intake of calcium was also found to have a significant protective effect among
men. Men whose average daily intake was 1400 mg or more reduced their risk by 56
per cent as compared to men whose daily intake was 400 mg or less. The
researchers point out that many of the patients with high intakes of the
protective micronutrients were using supplements and question whether the normal
American diet contains enough of these micronutrients to offer any significant
protection.
Patients with end-stage renal disease often die from a heart attack or other
cardiovascular complications. Researchers at the Cleveland Clinic Foundation now
provide compelling evidence that this increased risk of cardiovascular disease
among kidney patients is, to a large extent, due to the fact that they tend to
have high blood concentrations of homocysteine (an amino acid formed in the
metabolism of methionine). The study involved 176 dialysis patients with
end-stage renal disease. The researchers found that the kidney patients had much
higher homocysteine concentrations in their blood than does the normal
population (26.6 versus 10.1 micromol/liter). They also discovered that kidney
patients who had a homocysteine level above 27.8 micromol/liter were three times
more likely to suffer a cardiovascular event than were kidney patients with
lower concentrations. Not surprisingly, the researchers also found that kidney
patients who suffered cardiovascular events had lower levels of folate, vitamin
B-12, and vitamin B-6 (pyridoxine) than did kidney patients who did not suffer
such events. The researchers conclude that kidney patients may need more vitamin
B-6 supplementation than previously thought. They also suggest that
supplementation with folic acid (15 mg/day or more) together with adequate doses
of vitamins B-12 and B-6 may be effective in counteracting the increased risk of
cardiovascular disease found among patients with end-stage renal disease.
A low or deficient blood level of folate (folic acid) has been detected in 15 to
38 per cent of adults suffering from depression. There is now increasing
evidence that supplementation with therapeutic amounts of folate can
significantly improve the condition of depressed patients. In a recent trial
involving 20 elderly patients with depressive disorders, treatment with 50
mg/day of methylfolate was associated with an 81 per cent response rate within
six weeks. Folate supplementation (15 mg/day of methylfolate) has also been
found to markedly improve the effect of treatment with standard antidepressants.
Researchers at the Harvard Medical School point out that many drugs, some
chronic diseases (eg. rheumatoid arthritis), certain cancer treatments,
alcoholism, and a poor diet can all lead to a folate deficiency and the
potential for depression. They conclude that folate supplementation may play a
useful role in the treatment of depression, but caution that the daily dosage
required has to be carefully determined as too high a dose may cause sleeping
problems, irritability, and hyperactivity.
It is estimated that the treatment of preventable illnesses absorbs as much as
70 per cent of total health care costs in the United States. Researchers at the
Roche Vitamins Laboratory have just published a study which clearly demonstrates
that nearly $20 billion in hospital charges alone could be saved every year if
all women of childbearing age were to supplement with zinc and folic acid and if
all people over 50 years of age were to supplement with vitamin E. The
researchers evaluated all reports available in the MEDLINE database dealing with
the association between vitamin intake and the incidence of disease. There are
more than 4600 babies born every year in the United States with neural tube
defects. Research has shown that 70 per cent of these cases could be prevented
if all women of childbearing age were to supplement with 0.4-0.8 mg of folic
acid daily in addition to having a daily dietary intake of 0.15-0.2 mg folate.
Cardiovascular birth defects and complications associated with low birth weight
incur hospital charges of almost $6 billion/year. These conditions could be
largely prevented if women of childbearing age supplemented with folic acid plus
15-20 mg of zinc per day. Vitamin E supplementation is an effective preventive
measure against coronary heart disease and heart attacks. Several large-scale
studies have shown that men and women who supplement with 100 IU/day of vitamin
E for two or more years reduce their risk of fatal coronary disease and
non-fatal heart attacks by 40 per cent. Another large study found that older
people (mean age: 62 years) can reduce their risk of having a heart attack by
over 75 per cent by supplementing with 400 IU/day or more of vitamin E for 1.4
years or more. The researchers point out that in addition to major health care
cost savings other benefits of supplementation include better quality of life,
longer life, and increased productivity. They also point out that the level of
supplements required for effective disease protection cannot be obtained through
even the most healthful diet. NOTE: This work was funded and performed by
Hoffmann-LaRoche Inc., a major manufacturer of vitamins and pharmaceuticals.
It is becoming increasingly evident that an elevated blood level of homocysteine
is a potent risk factor for cardiovascular disease. Recent studies also suggest
that high homocysteine levels may be associated with kidney disease, psoriasis,
breast cancer, and acute lymphoblastic leukemia. Extensive past research has
shown a close link between the development of neural-tube defects in babies and
the mother's homocysteine level prior to and during pregnancy. Researchers at
the University of British Columbia have just released a major report which
summarizes the current knowledge about homocysteine and its effect on health.
Homocysteine is formed in human tissues during the metabolism of methionine, a
sulfur- containing essential amino acid. A normal, desirable level is 10
micromol/L or less. A level of 12 micromol/L is considered borderline and levels
of 15 micromol/L or above are considered to be indicative of increased risk for
cardiovascular disease. Several factors (age, smoking, vitamin deficiencies, and
genetic abnormalities) have been linked to increased homocysteine levels.
Medications that interact with folate such as methotrexate, carbamazepine,
phenytoin, and colestipol/niacin combinations have also been linked to increased
homocysteine levels. The researchers reviewed 23 studies dealing with the
association between atherosclerosis and homocysteine levels and found that
patients with vascular diseases had an average level of homocysteine that was 26
per cent higher than the level in healthy subjects. One study found that a
homocysteine level of 4 micromol/L above normal corresponds to a 41 per cent
increase in the risk of developing vascular disease. Another study estimates
that the lives of 56,000 Americans could be saved every year if average
homocysteine levels were lowered by 5 micromol/L. The researchers conclude that
abnormally high homocysteine levels are a potent risk factor for cardiovascular
and several other diseases. They point out that elevated homocysteine levels
can, in most cases, be safely and effectively lowered by supplementation with as
little as 400 micrograms per day of folic acid. Other researchers have found
that a combination of folic acid (0.4-10 mg/day), vitamin B-12 (50-1000
micrograms/day), and vitamin B-6 (10-300 mg/day) is highly effective in lowering
homocysteine levels. (153 references). Medical doctors at the University of
Wisconsin echo the findings of the Canadian researchers in a separate report and
describe a case of a 57-year-old man who lowered his homocysteine level from 29
micromol/L to 2 micromol/L by supplementing with 800 micrograms/day of folic
acid for two months.
Researchers at the Harvard School of Public Health have just released a major
study which shows that a higher intake of folic acid and vitamin B-6
(pyridoxine) protects women against nonfatal heart attacks (myocardial
infarction) and fatal coronary heart disease (CHD). The study involved over
80,000 female nurses who in 1980 completed food frequency questionnaires. The
questionnaires were updated in 1984, 1986 and 1990 and also gathered information
on the use of vitamin supplements. By 1994 658 of the women had suffered a
nonfatal heart attack (MI) and 281 had died of coronary heart disease.
Statistical analysis showed that women whose intake of folate (folic acid)
exceeded 545 micrograms/day had a 31 per cent lower risk of having a heart
attack or fatal CHD than did women whose intake was less than 153
micrograms/day. Similarly, women whose intake of vitamin B-6 was greater than
5.9 milligrams/day had a 33 per cent lower risk. Women with the highest intake
of both folate and vitamin B-6 had a 45 per cent lower risk than women with the
lowest combined intake. These risk reductions were independent of other
cardiovascular risk factors such as smoking, hypertension, alcohol consumption,
and the intake of fiber, vitamin E and saturated, polyunsaturated and trans-
fatty acids. Multivitamins and other vitamin supplements were by far the largest
contributors to the intakes of both folate and vitamin B-6.
The researchers found a linear decline in the risk of CHD with increased
folate intake (5.8 per cent decrease for each 100 micrograms/day increase in
intake) in the range between 150 to 700 micrograms/day. They conclude that the
lowest risk was among women whose folate intake was above 400 micrograms/day and
whose vitamin B-6 intake was above 3 milligrams/day. These values are
considerably higher than the current Recommended Daily Allowances (RDAs) of 200
micrograms and 1.6 milligrams respectively. The researchers also point out that
almost 90 per cent of all American women have a folate intake below 400
micrograms/day with the average national intake being only 224 micrograms/day. A
high folate intake was found to be particularly important among women who
consumed one or more alcoholic drinks per day. In this group those with the
highest folate intake reduced their risk of MI and CHD by an astounding 73 per
cent when compared to women with a low intake. The researchers were not able to
evaluate the benefits of supplementation with more than 1000 micrograms/day of
folate.
Many studies have shown that patients with vascular disease, especially coronary
heart disease, have higher blood homocysteine levels than do healthy controls.
It is clear that the elevated homocysteine levels precede the onset of disease
and is unrelated to other risk factors. Epidemiological studies have shown that
a prolonged lowering of homocysteine levels of just 1 micromol/liter (in the
range of 10-15 micromol/l) could theoretically result in a 10 per cent reduction
in risk. It is known that homocysteine concentrations are inversely proportional
to blood levels of folic acid (folate), vitamin B-12, and vitamin B-6 and that
homocysteine levels can be lowered by supplementing with these vitamins. Medical
researchers at the Radcliffe Infirmary have reviewed the results of trials aimed
at lowering homocysteine levels by vitamin supplementation. The trials involved
1114 people with a mean age of 52 years (23 to 75 years); the average (mean)
duration of treatment was six weeks and the median baseline blood concentrations
of homocysteine and folate were 11.8 micromol/l and 11.6 nanomol/l respectively.
The researchers found that daily supplementation with 0.5-5.0 mg of folic acid
reduces homocysteine concentrations by 25 per cent. The reduction was
significantly greater among patients with high initial homocysteine levels, but
did not seem correlated with the amount of folic acid taken in the range of 0.5
to 5.0 mg. Supplementation with vitamin B-12 (0.5 mg/daily on average) lowers
homocysteine levels by an additional seven per cent, but no effect was noted for
vitamin B-6 supplementation with an average (mean) intake of 16.5 mg/daily. The
researchers conclude that oral supplementation with at least 0.5 mg of folic
acid and 1.0 mg of vitamin B-12 on a daily basis would lower homocysteine
concentration by 3-4 micromol/l theoretically corresponding to a 30-40 per cent
reduction in the risk of developing vascular disease. They recommend that
further large scale studies be done to evaluate the efficacy and safety of long
term use of folic acid and vitamin B-12 as a means of reducing the incidence of
vascular disease among high risk subjects.
Researchers at the University of Calgary report that elderly people with low
blood levels of folic acid (folate) are more likely to suffer a stroke than are
people with normal to high levels. Their study involved 1171 subjects aged 65
years and older who were enrolled in the Canadian Study of Health and Aging. The
researchers found that participants with a folate level below 9.3 nmol/L had a
relative risk for ischemic stroke of 1.37. They also discovered that people with
low folate levels were more likely to be depressed or demented, tended to have a
history of weight loss, and were more apt to rate their health as poor. The
researchers conclude that folate deficiencies in elderly people can have serious
implications and point out that these deficiencies are easily, inexpensively,
and rapidly correctable through supplementation.
A deficiency of folate (folic acid) prior to and during preganancy increases the
risk of giving birth to a baby with neural tube defects. A lack of folate has
also been linked to an increased risk of cardiovascular disease. Now researchers
at the Harvard Medical School report that women with a high folate intake
decrease their risk of developing colon cancer by as much as 75 per cent. Their
study which began in 1980 involved 88,756 female nurses. The nurses completed
food frequency questionnaires in 1980, 1984, 1986, and 1990 and also provided
information about their use of vitamins, lifestyle factors, and family history
which could affect their risk of colon cancer. During the period from 1980 to
June 1994 442 of the women developed colon cancer. Statistical analysis showed
that women who had supplemented with multivitamins containing folic acid (>400
micrograms/day) for 15 years or more had a four times lower risk of colon cancer
than did women whose daily intake had been 200 micrograms/day or less. This
association remained true after adjusting for age, family history of colorectal
cancer, aspirin use, smoking, weight, degree of physical activity, and intake of
red meat, alcohol, methionine and fiber. Adjustment for intake of vitamins A, C,
D, E and calcium did not alter the folate/colon cancer correlation. However, it
was clear that the benefits of folate became evident only after 15 years or more
of supplement use although smaller statistically non-significant risk reductions
were noted after five years. The risk reduction associated with folate
supplementation was particularly evident among women with low methionine levels.
Folate is essential in the regeneration of methionine and a deficiency may lead
to abnormalities in DNA synthesis and repair - mechanisms which may influence
the development of colon cancer. The researchers found a significantly stronger
correlation between the intake of folate from supplements and a reduced colon
cancer risk than between the intake of dietary folate and reduced risk. They
ascribe this to the relatively low bioavailability of folate from food sources
and conclude that long term use of multivitamins containing folic acid reduces
the risk of colon cancer in women. Other studies have shown that folic acid
supplementation also reduces colon cancer risk in men. NOTE: Certain birth
control pills and drugs such as methotrexate can markedly lower folate levels in
the body.
Cancer of the colon or rectum is now the second most common cause of cancer
deaths in the United States. There were almost 200,000 new cases and over 59,000
deaths from colorectal cancer in 1996 alone. Colon cancer is preceded by the
occurrence of malignant polyps (adenomatous polyps); non-malignant polyps
(hyperplastic polyps) may also be present in the colon and rectal area.
Researchers at the University of Toronto have just completed a study which shows
that the folate (folic acid) level in the lining (mucosa) of the colon is
significantly lower among patients with malignant polyps than among patients
with benign polyps. Their study involved 30 patients over the age of 18 years
who had been referred to the New England Medical Center for colonoscopy.
Biopsies of normal mucosa (at least 10 cm from polyps) showed that the presence
of adenomatous polyps was associated with a significantly lower mucosal folate
level than was the presence of hyperplastic polyps. Although mucosal folate
levels correlated reasonably well with the folate concentration in blood serum
and red blood cells, these indicators were not sufficiently sensitive to predict
whether polyps would be malignant or not. Blood levels of homocysteine were
found to correlate well with mucosal folate levels and an elevated homocysteine
level was also found to correlate with the presence of adenomatous polyps. The
researchers suggest that people with malignant polyps may have an impairment in
their folate metabolism which would account for their higher homocysteine
levels.
Folates occur naturally in foods such as spinach and broccoli. Folic acid
is a synthetic form of folate used in supplements and fortified foods. A folate
deficiency has been linked to neural tube defects, cardiovascular disease, and
colon cancer. The Food and Nutrition Board of the US Academy of Sciences has
recently updated the Recommended Dietary Allowances for folate. They are now 400
micrograms/day for adults, 600 micrograms/day for pregnant women, and 500
micrograms/day for lactating women. Folic acid has been found to be 1.7 times
more bioavailable than folate from food so 100 micrograms of folic acid has the
equivalent effect of 170 micrograms of food folate. The Tolerable Upper Intake
Level for supplemental folic acid has been set at 1000 micrograms/day based on
the observation that an intake of 5 mg or more per day may hide the progression
of neurologic disorders in patients suffering from a deficiency of vitamin B12.
An inadequate intake of folic acid is firmly associated with an increased
risk of vascular disease and, among women of childbearing age, with a
significantly heightened risk of giving birth to a baby with neural tube
defects. Now a team of researchers from the universities of Oxford and Bergen
(Norway) report that low folate levels are associated with an increased risk of
developing Alzheimer's disease (AD). Their study which spanned the period 1988
to 1996 involved 164 patients with a clinical diagnosis of AD and 108 control
subjects. The AD diagnosis was confirmed by autopsy in 76 of the 164 patients
who died during the study. The researchers found that AD patients had
significantly lower blood levels of folic acid and vitamin B12 (cobalamin) than
did controls. They also had significantly higher levels of the amino acid
homocysteine. Homocysteine is a strong risk factor for vascular disease and its
level has been found to be inversely proportional to the level of folic acid in
the blood. Study participants with homocysteine concentrations equal to or
higher than 14 micromol/liter were found to have a 4.5 fold higher risk of AD
than did participants with a homocysteine level at or below 11 micromol/liter.
This association held true even when corrected for age, sex, social class,
cigarette smoking, and level of apolipoprotein E epsilon 4 (a known risk factor
for the development of AD). Study participants with folate levels in the lower
third of the overall distribution had a 3.3 fold higher risk of AD when compared
to subjects in the upper third. Similarly, participants in the lower third of
vitamin B12 levels had a 4.3 times higher risk of AD as compared to subjects in
the upper third. The researchers also observed that disease progression was more
rapid among AD patients with high initial homocysteine levels. They conclude
that high homocysteine levels are an important risk factor for AD and that this
risk can be significantly reduced by ensuring an adequate intake of folic acid
and vitamin B12. They suggest that daily supplementation with 0.5 to 5 mg of
folic acid and 0.5 mg of vitamin B12 (cyanocobalamin) will lower the typical
homocysteine levels found in Western populations by about a third.
There is increasing evidence that high blood levels of the amino acid
homocysteine increases the risk of vascular disease, coronary heart disease,
neural tube defects, and Alzheimer's disease. Folic acid supplementation is
known to lower homocysteine levels and laws have recently been passed in the
United States mandating folic acid fortification of bread and cereal. Now
researchers at the University of Bonn report that folic acid's homocysteine
lowering capacity can be markedly increased by also supplementing with vitamin
B-12 (cobalamin). Their study involved 150 young, healthy women (average age of
24 years) who after a four-week washout period were randomized into three
groups. Group 1 received a daily supplement of 400 micrograms of folic acid,
group 2 received 400 micrograms/day of folic acid and 6 micrograms/day of
vitamin B-12, and group 3 received 400 micrograms/day of folic acid and 400
micrograms/day of vitamin B-12. After four weeks the average concentration of
plasma homocysteine had dropped by 11 per cent in group 1, 15 per cent in group
2, and 18 per cent in group 3. The researchers noted that study participants
with high initial homocysteine concentrations benefitted more from
supplementation than did women with lower initial homocysteine levels. It was
also noted that vitamin B-12 levels increased significantly over the four-week
period in the women whose supplements included vitamin B-12. This provides
further proof that oral vitamin B-12 is indeed adequately absorbed. The
researchers conclude that the benefits of folate supplementation can be markedly
enhanced by the addition of vitamin B-12. They point out that vitamin B-12
deficiency is widespread especially among the elderly. The addition of vitamin
B-12 to folic acid supplements also prevents the possibility that
supplementation with just folic acid could mask pernicious anemia resulting from
a vitamin B-12 deficiency which in turn may lead to irreversible nerve damage.
An elevated level of homocysteine is a risk factor for cardiovascular disease,
stroke, and Alzheimer's disease and also increases the risk of a pregnant woman
giving birth to a baby with neural tube defects. Supplementation with folic acid
is known to lower homocysteine levels, but it is not known exactly how much is
required and how long it takes to become effective. Researchers at the Nijmegen
University Hospital have just completed a study aimed at answering these
questions. The trial involved 144 healthy women (with normal homocysteine
levels) between the ages of 18 and 40 years. The women were randomly allocated
to one of three groups. Group 1 received 500 micrograms of folic acid daily for
a four-week period, group 2 received 500 micrograms every second day (250
micrograms/day), and group 3 received a placebo. Blood samples were taken at the
start of the trial and after one, two and four weeks when the supplementation
phase ended. Samples were also taken four and eight weeks after the end of the
supplementation to see how long its effect would last. Supplementation with both
500 micrograms/day and 500 micrograms every second day was found to be
effective. Homocysteine levels decreased by an average 22 per cent in the women
taking 500 micrograms/day and by 11 per cent in the ones taking 500 micrograms
every second day. The level of folate in plasma and red blood cells also
increased significantly. The homocysteine levels increased again when
supplementation was stopped, but were still well below original levels eight
weeks later. The major part of the drop in homocysteine level in the 500
micrograms/day group took place within the first two weeks. In view of the fact
that neural tube defects develop in the third or fourth week of pregnancy it may
be worthwhile to start taking folic acid immediately after missing the first
period; although, of course, it would be better to start four weeks before a
planned pregnancy. The magnitude of the observed drop in homocysteine
concentration upon supplementation was found to be highly dependent on the
initial level. Women with high levels (14.3 micromol/L) experienced a drop of
around 4 micromol/L while women with lower initial levels only experienced drops
of about 1 micromol/L.
Hearing loss is the most common impairment among the elderly after heart
problems, hypertension, and arthritis and affects more than 28 million
Americans. Researchers from the Centers for Disease Control and Prevention and
the University of Georgia believe that age-related hearing loss may be partially
caused by vitamin deficiencies. They have just released a report which supports
this hypothesis. Their study involved 55 healthy women between the ages of 60
and 71 years. The women were all given a hearing test using a diagnostic
audiometer according to Standard S3.6 of the American National Standards
Institute and also had fasting blood samples taken. The blood samples were
analyzed for serum vitamin B12, serum folate, and folate levels in the red blood
cells. The researchers discovered that women with impaired hearing (less than 20
dB hearing level) had a 38 per cent lower serum level of vitamin B12, a 31 per
cent lower folate level in the red blood cells, and a 25 per cent lower folate
level in the blood serum. They speculate that poor folate and vitamin B12 status
may somehow lead to deterioration of the nerves and blood vessels supplying the
auditory system perhaps through a mechanism involving homocysteine.
Folic acid
and colon cancer
Colorectal cancer (cancer of the colon or rectum) is the third-leading
cancer in the United States with more than 130,000 new cases reported every
year. Previous research has shown that a high consumption of meat and a low
intake of fruits and vegetables substantially increase the risk of developing
colorectal cancer. Now researchers at the New York University School of Medicine
report that women with a low level of folate (folic acid) in their blood serum
have twice the risk of colorectal cancer than do women with higher levels. Their
study involved 15,785 women who were part of the New York University Women's
Health Study begun in 1985. By the end of 1994 105 of the women had developed
colorectal cancer. These women were matched with 523 controls and folate intake
and blood levels of folate and homocysteine were compared. Women with the
highest serum level of folate (more than 31 nanomol/L) had about half the risk
of developing colorectal cancer than did women with levels below 12 nanomol/L.
Women with the highest levels of homocysteine (more than 12 micromol/L) had a 70
per cent increase in risk compared with women whose levels were below 8
micromol/L. About 39 per cent of the total folate intake reported came from
vitamin/mineral supplements. The researchers conclude that folates may protect
against colorectal cancer, but recommend larger clinical trials to further
support this contention.
A high blood level of the amino acid homocysteine has been linked to an
increased risk of atherosclerosis and thrombosis. It is known that oral
supplementation with folic acid will lower homocysteine levels to acceptable
norms, but it is not clear just how much folic acid is required to achieve this
effect. Now researchers at the Cleveland Clinic Foundation report that the
amount of folic acid (400 micrograms) found in most multivitamin preparations is
sufficient to lower homocysteine levels in heart disease patients. Their
experiment involved 95 patients who had either had a heart attack or suffered
from advanced atherosclerosis. The patients were divided into four groups with
one group receiving 400 micrograms/day (0.4 mg/day) of folic acid, one group
receiving 1 mg/day, one group receiving 5 mg/day, and the fourth group receiving
a placebo. All patients receiving folic acid also received 12.5 mg of vitamin B6
per day and 500 micrograms of vitamin B12. After 90 days the plasma homocysteine
levels had dropped from 13.8 to 9.6 micromol/L in the 400 micrograms/day folic
acid group, from 13.0 to 9.8 micromol/L in the 1 mg/day group, and from 14.8 to
9.7 micromol/L in the 5 mg/day group. Also after 90 days the plasma levels of
folic acid had risen from 28 nanomol/L in the placebo group to 63 nmol/L in the
400 micrograms/day supplement group, to 80 nmol/L in the 1 mg/day group, and to
162 nmol/L in the 5 mg/day group. Vitamin B6 levels rose from 75 nmol/L to about
250 nmol/L in the supplemented groups and vitamin B12 levels rose from about 300
picomol/L to 525 picomol/L. The researchers conclude that a daily dose of 400
micrograms of folic acid combined with vitamins B6 and B12 will normalize
homocysteine levels in heart disease patients.
People suffering from Parkinson's disease have an increased risk of heart
attacks and strokes. A team of German and Swiss medical researchers believe they
have uncovered the reason for this and propose a simple solution to the problem.
The researchers studied a group of 48- to 73-year-old people. Fifteen of them
had Parkinson's disease and were treated with levodopa plus decarboxylase
inhibitor (Sinemet), 15 had Parkinson's disease, but were not treated as yet,
and 15 were healthy controls. All study participants had their homocysteine
levels measured after a 10-hour fast. The drug-treated Parkinson's patients had
an average level of 17.3 micromol/L as compared to 9.1 micromol/L in the
untreated group, and 9.2 micromol/L in the group of healthy controls. Other
research has found that men with a level of 15 micromol/L increase their risk of
coronary heart disease by 60 per cent while women increase it by 80 per cent.
The risk of a stroke at the 15 micromol/L is two to five times higher than at
the 10 micromol/L level in both men and women and the risk of peripheral
vascular disease (eg. intermittent claudication) is seven times higher among
people with elevated levels. The researchers believe that prolonged treatment
with levodopa and decarboxylase inhibitor increases the blood level of
homocysteine resulting in a greater risk for heart disease and stroke. They
point out that elevated homocysteine levels can be lowered easily and
effectively by supplementation with folic acid (400-800 micrograms per day or
more depending on homocysteine level). The research team concludes that
Parkinson's patients who are treated with levopoda should have their
homocysteine levels monitored on a regular basis and should supplement with
folic acid as required. (Editor's Note: Folic acid is non-toxic and no cases of
overdosing have ever been reported. In these times of tight medical resources it
would seem reasonable to suggest that Parkinson's patients on levopoda routinely
supplement with 400-800 micrograms per day - unless, of course, their physician
has specific objections to this).
Folates (derivatives of folic acid) play a key role in the synthesis, repair,
and methylation of DNA. It is therefore not surprising that a deficiency in this
essential B vitamin has been implicated in Alzheimer's disease, atherosclerosis,
heart attack, stroke, osteoporosis, depression, dementia, cleft lip and palate,
hearing loss, Raynaud's phenomenon, and of course, neural tube defects.
There is now also evidence that a folate deficiency may be involved in the
development of certain cancers. Dr. Young-In Kim, MD of the University of
Toronto presents an overview of the current knowledge regarding the role of
folates in cancer prevention. Some 20 studies have been published regarding the
association between colorectal cancer (cancer of the colon or rectum) and folate
status. Collectively, these studies suggest that people with a high intake of
folates can reduce their risk of developing colorectal cancer by about 40 per
cent when compared to people with low intakes. A study involving almost 90,000
American female nurses concluded that nurses who had been supplementing with 400
micrograms/day or more of folic acid for 15 years or more had a 75 per cent
reduction in the risk of colorectal cancer when compared to people who did not
supplement. The evidence concerning folates and breast cancer is not quite as
clear. Studies have shown that even moderate alcohol consumption increases the
risk of breast cancer and that this risk can be counteracted by supplementing
with folic acid. The jury is still out on whether folate supplementation reduces
the risk among non-drinkers although one study did show that postmenopausal
women could decrease their risk of developing breast cancer by supplementing
with folic acid. Another study involving 300 premenopausal women found a 50 per
cent lower risk among women whose intake exceeded 304 micrograms/day. Other
studies, however, have failed to confirm this effect.
A major study involving over 29,000 male, Finnish smokers found that those who
developed pancreatic cancer had a significantly lower blood serum level of
folate than did those who did not. A baseline serum folate level above 4.45
ng/mL was associated with a 55 per cent risk reduction when compared to levels
below 3.33 ng/mL. An Australian study found a 64 per cent difference in risk
between men with the highest folate intake and those with the lowest intake.
Dr. Kim concludes that a moderate increase in folate intake can materially help
reduce the risk of certain cancers, but cautions that people who already have
cancer should not increase their folate intake as there is evidence that high
folate levels may accelerate the growth of existing tumours.
|
What is folic acid?
Folic acid is a water soluble B-vitamin that helps build healthy cells. "Water soluble" means it does not stay in your body for very long, so you need to take it every day to help prevent neural tube defects. During periods of rapid growth, such as pregnancy and fetal development, the body's requirement for this vitamin increases. There are two different forms of folic acid:
Our bodies absorb the synthetic form of folic acid more easily than the natural form. A diet rich in folate is important, however the average American diet does not supply enough folic acid.
Folic acid recommendation SBAA advises the 60 million women of childbearing age not to depend on food alone for folic acid. SBAA urges women to follow the 1992 U.S. Public Health Service folic acid recommendations:
Many things can affect a baby, including family genes and things women may come in contact with during pregnancy. Taking folic acid cannot guarantee having a healthy baby, but it can help. Since NTDs occur early in pregnancy, often before a woman knows she is pregnant, it is important to take folic acid every day. Taking folic acid before and during early pregnancy reduces the risk of spina bifida and other neural tube defects. Recent prevention studies Randomized control trials and observational studies have shown that if all women who could become pregnant were to take a multivitamin with the B-vitamin folic acid, the risk of neural tube defects could be reduced by up to 75%. For women at higher risk for spina bifida or other neural tube defects, an increased level of folic acid is recommended by prescription. Research has shown that 4000 micrograms of folic acid reduces the risk of neural tube defects for these women. Folic acid fortification In 1998, breads and enriched cereal grain products were fortified with synthetic folic acid by order of the Food and Drug Administration (FDA). All U.S. wheat, rice and corn are fortified at the rate of 140 micrograms per 100 grams of grain, thus providing most people with 100 micrograms of folic acid daily. The addition of folic acid to all food grains was based on research at the time, which indicated that only about 25 percent of women of childbearing age regularly consume enough folic acid in the form of a vitamin supplement. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The U.S. Public Health Service recommended in September 1992 that all women of childbearing age consume 400 micrograms (ug) of folic acid daily to reduce their risk of having a pregnancy affected with spina bifida or other neural tube defects. Folic acid is a B vitamin. For women, this amount of folic acid on a daily basis spina bifida or anencephaly, both of which are neural tube defects (NTDs) in the baby.
PHS suggested several approaches by which this level could be reached:
In keeping with the recommendations of PHS and the FDA Food Advisory Committee called to study these issues, the Food and Drug Administration is requiring that folic acid be added to specific flour, breads and other grains. These foods were chosen for fortification with folate because they are staple products for most of the U.S. population, and because they have a long history of being successful vehicles for improving nutrition to reduce the risk of classic nutrient deficiency diseases.
These fortified foods include most enriched breads, flours, corn meals, rice, noodles, macaroni and other grain products.
Under the terms of the new rule:
FDA also emphasizes that adequate levels of folic acid, in the form of folate, can be obtained by eating natural sources such as:
In addition, women can assure adequate intake by taking dietary supplements containing folic acid.
The new rule takes account of the finding in PHS' recommendation that total folate consumption should be kept under 1 mg per day. This is because higher intake may complicate the diagnosis of pernicious anemia, one form of vitamin B12 deficiency, which especially affects older people.
Neural tube defects, including spina bifida and anencephaly, are a common birth defect.
Since NTDs develop very early in pregnancy (18-30 days after conception), often before a woman knows she is pregnant, it is essential that adequate intake of folic acid be maintained throughout the childbearing years.
Women who have had a prior NTD-affected pregnancy are at high risk of having a subsequent affected pregnancy. When these women are planning to become pregnant, they should consult their physicians for advice.
Because the effects of high intakes of folic acid are not well known, but do include complicating the diagnosis of vitamin B12 deficiency, care should be taken to keep total folate consumption under 1 mg per day, except under the supervision of a physician.
The FDA rule is designed to keep total folic acid intake under the 1 mg level.
Addition of iodine to salt was one of the earliest successful fortification programs. Iodine fortification was initiated in the U.S. in 1924 to prevent goiter, cretinism and other symptoms of severe iodine deficiency.
In the early 1930s, vitamin D was first added to cow's milk to aid in absorption of calcium and phosphorus, preventing development of rickets.
In 1938, voluntary enrichment of flours and breads was initiated to prevent the development of deficiency diseases in the general population. Enrichments included thiamin for beriberi, niacin for pellagra, riboflavin essential for proper functioning of vitamin B6 and niacin, and iron for iron deficiency anemia. Mandatory requirements were effective in 1943.
There are various other fortification requirements to enhance the quality of food such as vitamin A added to low and nonfat cow's milk and certain other dairy products, and lysine added to certain corn products to enhance protein quality.
The message to pregnant women is clear. A little investment in nutrition now pays off richly in your baby's health later.
For that reason, the Food and Drug Administration proposed last October that all bread and grain products be fortified with folic acid, one of the B vitamins. Just 0.4 milligrams (mg) of the nutrient every day can greatly reduce the risk of neural tube defects, which affect the brain and spinal cord.
Folate is in many healthful foods. (Folate and folic acid are interchangeable terms. Folic acid is the synthetic form of folate, which is found naturally in some foods.) A bowl of lentil soup or fortified breakfast cereal, a large spinach salad, or a tall glass of orange juice will put a woman well on her way to 0.4 mg of folic acid.
The tricky part is that neural tube defects occur in an embryo before a woman may realize she's pregnant. Since more than half of pregnancies are unplanned, FDA has taken steps to fortify food so that all women of childbearing age get a daily dose of folic acid.
Without it, most women 19 to 50 get only 0.2 mg of folic acid each day, according to U.S. Department of Agriculture estimates. If the regulation is finalized within the next six months, FDA estimates that the fortified food will reach the plates of more than 90 percent of American women by 1995. If the move is successful in boosting women up to 0.4 mg of folic acid daily, it could cut the incidence of neural tube defects in this country by as much as half.
Despite this benefit, the decision to add folic acid to food is difficult because it's so tricky to estimate what people eat. Most of the folic acid studies have been done with vitamin pills, not plates of food. It's hard for scientists to translate the results of those controlled studies into recommendations for the ever changing eating habits of Americans.
"As a scientific and policy matter, it is one of the more difficult issues I have confronted," said FDA Commissioner David A. Kessler, M.D., addressing a meeting of the March of Dimes last January. "Before we fortify the food supply for 250 million Americans, we have to make sure we get it right."
The amount of folic acid FDA has proposed adding is tiny--40 micrograms per 100 grams (3.5 ounces) of bread and other grain products like flour, rolls, buns, corn grits, cornmeal, farina, rice, and noodles. A microgram is one millionth of a gram. This alone will probably not meet a woman's need for 0.4 mg (400 micrograms) each day, depending on what she eats. She will have to get the rest of her folic acid either from a vitamin supplement or from other foods in her diet. FDA is considering whether to allow food manufacturers to make health claims about which foods and vitamin supplements are rich in folic acid.
This is no problem for those who eat foods rich in folate. Leafy green vegetables, citrus fruits, beans, and fortified breakfast cereals are great folate sources. In fact, anyone who follows the USDA Food Pyramid Guide, which suggests 3 to 5 servings of vegetables, 2 to 4 of fruits and 6 to 11 servings of grains daily, can easily get 400 to 500 micrograms of folate each day.
The amount FDA is proposing be added to food is set below the level likely to cause harm from too much folate. A number of scientists believe that up to 1 mg (one-thousandth of a gram) of folic acid per day is safe. So even if someone followed USDA's guide, including eating fortified bread, and took a multivitamin with another 400 micrograms of folic acid, he or she would still be within safe limits.
The main problem is for older Americans. One in five people 65 to 95 lack sufficient vitamin B12, a deficiency that can cause pernicious anemia. Extra folic acid can mask the symptoms of the condition, which may lead to permanent nerve damage if left untreated.
FDA's proposal has drawn both support and criticism from a wide range of health officials and scientists. Experts in health and nutrition have taken opposite positions on the issue.
For instance, a working committee of scientists from the national Centers for Disease Control and Prevention in Atlanta wants FDA to require the addition of even more folic acid than proposed. The committee believes the amount FDA has proposed is insufficient to prevent large numbers of neural tube defects.
"I've seen the trauma of neural tube defects. It's a very stressful situation for a family," says Joseph Mulinare, M.D., a pediatrician and medical epidemiologist at CDC. As a member of CDC's working group on folic acid, Mulinare and his colleagues would like to see FDA require two and a half times more folic acid in breads than it is considering.
On the other hand, other scientists have urged caution before fortifying the food supply. "I'm a little nervous about using large doses of folic acid," says James Mills, M.D., chief of pediatric epidemiology at the National Institute of Child Health and Human Development. "We don't really know what will happen if we add folic acid to the diets of 250 million people, and it may be difficult to identify any adverse effects."
Some nutritionists oppose fortification on principle, arguing that women can get all the folic acid they need from a well-balanced diet. And some consumer groups urged FDA to act sooner to prevent birth defects.
Since the Public Health Service recommended in 1992 that FDA require folic acid fortification, the agency has worked toward a policy that will reduce birth defects without harming anyone.
"FDA is criticized for being conservative, but in the area of uncertainty, it's best to be cautious," says Jeanne Rader, Ph.D., a biochemist with FDA's Office of Food Labeling. "If you err, you have to err on the side of caution."
There is good reason for health officials to seek to reduce the number of neural tube defects.
Neural tube malformations are serious birth defects that cause disability or death. They are the most common disabling birth defects, affecting between one and two infants out of every 1,000 births in the United States.
There are two main kinds of neural tube defects: anencephaly and spina bifida. A baby with anencephaly does not develop a brain, and dies shortly after birth.
Spina bifida is a defect of the spinal column. If the vertebrae (bones of the spinal column) surrounding the spinal cord do not close properly during the first 28 days after fertilization, the cord or spinal fluid bulge through, usually in the lower back.
While once all these children died, with proper medical treatment, about 85 to 90 percent of them now live to adulthood, according to the Spina Bifida Association of America. Depending on the severity of the condition, they have varying degrees of paralysis and incontinence.
There are two major forms of the condition. The mild form, spina bifida occulta ("hidden") is only a small gap in the spine, with a dimple in the skin covering it. There are usually no symptoms. Some Americans have spina bifida occulta and don't even know they have it, according to the National Information Center for Children and Youth with Disabilities.
The more disabling form is spina bifida aperta, which produces an noticeable sac on the infant's back. A small sac, called a meningocele, produces little or no muscle paralysis or incontinence once it is repaired.
But in 90 percent of all spina bifida cases, a portion of the undeveloped spinal cord itself protrudes through the spine and forms a sac protruding on the baby's back. Any portion of the spinal cord outside the vertebrae is undeveloped or damaged, causing paralysis and incontinence. This is called a myelocele (or meningomyelocele), and it is what most people refer to as spina bifida.
The location of the sac determines how severely disabled the child will. In general, the higher it is on the spinal column, the more paralysis there is.
Doctors must repair the opening of the spine shortly after birth or the child will die. Other major surgeries often follow in the child's first years. About 85 percent of children with spina bifida develop hydrocephalus, an accumulation of cerebrospinal fluid surrounding the brain. This fluid must be drained to the abdomen or bloodstream with a surgically implanted tube.
Some children with spina bifida develop foot and knee deformities caused by an interruption of spinal nerve circuits. Many patients require leg braces, crutches, and other devices to help them walk. They may have learning disabilities, and about 30 percent of children have slight to severe mental retardation, especially if they have chronic hydrocephalus. Chronic bladder infections and kidney problems require lifelong medical attention.
Despite their need for medical attention, children with spina bifida can learn to care for many of their own needs. They often learn to catheterize themselves, for instance, so they can attend regular schools. With proper medical care, a person with spina bifida can live a long and productive life.
Scientists first hypothesized in the 1950s that diet had something to do with neural tube defects. The incidence of these conditions has always been higher in low socioeconomic populations in which women, presumably, have poorer diets. Also, babies conceived in the winter and early spring are more likely to be born with spina bifida, perhaps caused by a lack of fresh foods in early pregnancy.
In addition, researchers discovered in the 1960s that folic acid deficiency causes birth defects in animals. The nutrient plays an important role in cell division and growth.
But there appear to be factors other than nutrition in the development of spina bifida. Genetics also seems to play a role. People of Northern European and Hungarian ancestry have the highest rates of the disease, and the condition tends to run in families, although not consistently.
In fact, 90 to 95 percent of children with spina bifida are born to women who have no other children or anyone in their family with the defect.
In 1991, a study by British researchers found that women who already had one child with a neural tube defect could reduce by 72 percent the chance of another child being affected if they took high doses of folic acid.
Later studies showed that women with no history of giving birth to children with neural tube defects could reduce their risk by up to 60 to 75 percent if they took dietary supplements of between 0.4 mg and 0.8 mg of folic acid daily. The more folic acid the women took, the less was their chance of having a baby with a neural tube defect. One study also suggested that folate from food alone reduced the risk.
Scientists are in general agreement that folic acid reduces the risk of neural tube defects. What remains to be seen is the effect it will have on the general population if it is added to breads and grains.
Historically, fortification with nutrients has produced good results. The United States has had success in fortifying bread with other B vitamins: riboflavin, niacin and thiamin, for example. Those nutrients were added to bread years ago and have virtually eliminated once common and serious diseases such as pellagra. Those vitamins were added in very small quantities, however. Whether bread fortified with higher doses of folic acid will work the same wonders without ill effects is not easy to determine.
Says FDA's Rader, "As a consumer, what you want is something that's going to be safe and effective, and that's not going to be dangerous, either.
"Fortifying the nation's food supply is not something where someone waves a magic wand and makes it happen. It's a very serious matter," she adds. "People think this is an easy decision, but it's not."
Micrograms
(per 100 g of food-3.5 oz)
dark-green leafy vegetables 120-160
other vegetables 40-100
fruits (particularly citrus) 50-100
beans (legumes) 50-300
whole grains 60-120
breakfast cereals 100 or 400
A number of tests are available to diagnose neural tube defects before a baby is born.
One such test, the maternal serum alpha-fetoprotein (AFP) test, is a blood test for the mother at 16 to 18 weeks into the pregnancy. It was approved by FDA in the early 1980s as a prenatal test for neural tube defects (a second approved use is as an aid for a certain kind of testicular cancer).
The test measures alpha-fetoprotein, a substance produced by the fetus and secreted into the amniotic fluid, eventually entering the mother's blood. As it grows, the baby produces increased amounts of AFP. The level of AFP in mother's blood peaks at about 30 to 32 weeks.
Abnormally high amounts of AFP may indicate a baby has a neural tube defect. But the test is not perfect.
Up to 20 percent of spina bifida cases do not produce high levels of AFP, so the test does not detect them. And when the test does indicate a high level of AFP, a neural tube defect is present only 10 percent of the time. Most commonly, the AFP level is high because the pregnancy is just further along than was thought.
Other possible causes of high AFP values are that the mother is carrying twins or that there is a placental problem. Women with diabetes or liver disease also have elevated AFP levels. Birth defects in the fetus such as kidney and heart problems may produce high AFP levels as well.
If a woman has an elevated AFP test, her doctor will usually give her a second AFP test, followed by ultrasound. If still no explanation for a high AFP value can be found, the physician may perform amniocentesis. In this test, the doctor takes a sample of the amniotic fluid and measures it for AFP levels. The results of these tests together will identify a high percentage of spina bifida cases.